| Description |
1 online resource (265 pages) : illustrations. |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
| Series |
Pharmacology-research, safety testing, and regulation series |
|
Pharmacology-research, safety testing, and regulation series.
|
| Bibliography |
Includes bibliographical references and index. |
| Note |
Online resource; title from PDF title page (ebrary, viewed January 2, 2014). |
| Contents |
CLOPIDOGREL: PHARMACOLOGY, CLINICAL USES AND ADVERSE EFFECTS; CLOPIDOGREL: PHARMACOLOGY, CLINICAL USES AND ADVERSE EFFECTS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: CLINICAL REVIEW: PHARMACOLOGY OF TRADITIONAL AND MODERN ANTICOAGULANT AND ANTIPLATELET THERAPY; ABSTRACT; INTRODUCTION; THE COAGULATION PATHWAY; VITAMIN K ANTAGONISTS; XA INHIBITORS; RIVAROXABAN (XARELTO®); APIXABAN (ELIQUIS®); DIRECT THROMBIN INHIBITORS; LEPIRUDIN (REFLUDAN®); BIVALIRUDIN (ANGIOMAX®); DABIGATRAN (PRADAXA®); ADP ANTAGONISTS (THIENOPYRIDINES); TICLOPIDINE (TICLID®) |
|
CLOPIDOGREL (PLAVIX®)PRASUGREL (EFFIENT®); TICAGRELOR (BRILLINTA®); GLYCOPROTEIN IIB/IIIA INHIBITORS; ABCIXIMAB (REOPRO®); EFTIFIBATIDE (INTEGRILIN®); TIROFIBAN (AGGRASTAT®); HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ENOXAPARIN (LOVENOX, XAPARIN, CLEXANE®); FONDAPARINUX (ARIXTRA®); DISCUSSION; SUMMARY POINTS; REFERENCES; Chapter 2: CLOPIDOGREL IN NEUROINTERVENTIONAL SURGERY: INDICATIONS, COMPLICATIONS, CHALLENGES AND METHODS FOR MONITORING RESPONSE; ABSTRACT; ABBREVIATIONS; INTRODUCTION; INDICATIONS FOR CLOPIDOGREL IN NEUROINTERVENTIONAL SURGERY. |
|
NEUROLOGICALLY-RELEVANT HEMORRHAGIC COMPLICATIONS OF CLOPIDOGRELCOMPLICATIONS OF CLOPIDOGREL IN NEUROINTERVENTIONAL SURGERY; CHALLENGES IN USING CLOPIDOGREL FOR NEUROINTERVENTIONAL SURGERY; METHODS FOR CLOPIDOGREL MONITORING IN NEUROINTERVENTIONAL SURGERY; CONCLUSION; REFERENCES; Chapter 3: CLOPIDOGREL PHARMACOKINETIC: REVIEW OF EARLY STUDIES AND NOVEL EXPERIMENTAL RESULTS; ABSTRACT; 1. INTRODUCTION; 2. PHARMACOKINETICS OF CLOPIDOGREL CARBOXYLIC ACID AND CLOPIDOGREL; 3. CLOPIDOGREL ANALYTICAL CHALLENGES; 4. EXPERIMENTAL DATA ON CLOPIDOGREL ACYL GLUCURONIDE PK. |
|
5. CLOPIDOGREL ACTIVE METABOLITE PK6. EXPERIMENTAL DATA ON OXO-CLOPIDOGREL PK; 7. CONSIDERATIONS ON OTHER POTENTIAL METABOLITES OF CLOPIDOGREL; 8. OVERALL VISION OF CLOPIDOGREL METABOLISM AND PK; 9. POSSIBLE PD IMPACT OF CLOPIDOGREL PK; CONCLUSION; REFERENCES; Chapter 4: FROM MECHANISM TO THERAPEUTICS: OVERCOMING INTER-INDIVIDUAL VARIABILITY IN CLOPIDOGREL THERAPY; ABSTRACT; ABBREVIATION; INTRODUCTION; PHARMACOKINETICS (PK) AND METABOLISM OF CLOPIDOGREL; OVERCOMING INTERINDIVIDUAL VARIABILITY; CONCLUSION; REFERENCES; Chapter 5: MANAGEMENT OF CLOPIDOGREL HYPERSENSITIVITY; ABSTRACT. |
|
INTRODUCTION: CLOPIDOGREL METABOLISM AND INDICATIONSPRESENTATION AND INCIDENCE OF CLOPIDOGREL HYPERSENSITIVITY; DIAGNOSIS AND PATHOPHYSIOLOGY; PHARMACOLOGIC ALTERNATIVES TO CLOPIDOGREL; CLOPIDOGREL DESENSITIZATION; MANAGEMENT OF HYPERSENSITIVITY REACTION WITHOUT CLOPIDOGREL INTERRUPTION; CONCLUSION; ACKNOWLEDGMENT; REFERENCES; Chapter 6: CLOPIDOGREL AND GASTROINTESTINAL HARM; ABSTRACT; I. INTRODUCTION; II. CLOPIDOGREL AND GI HARM; III. CLOPIDOGREL AND PROTON PUMP INHIBITOR INTERACTIONS; V. PHARMACOKINETIC AND PHARMACODYNAMIC EVIDENCE FOR A CLOPIDOGREL-PPI INTERACTION; VI. GUIDANCE; CONCLUSION. |
| Subject |
Clopidogrel.
|
|
Pharmacology.
|
|
Pharmacology |
|
Pharmacologie.
|
|
pharmacology.
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Clopidogrel
|
|
Pharmacology
|
| Added Author |
Alesci, James P.
|
|
Victorino, Alexander.
|
| ISBN |
9781629483375 (electronic bk.) |
|
1629483370 (electronic bk.) |
|
9781629483368 |
| Standard No. |
DEBBG BV042793047 |
|
AU@ 000056889089 |
|
